Solasta Ventures is a venture capital firm and wholly-owned subsidiary of Aju IB Investment, focused on investing in innovative companies that advance the standard of care for diseases with unmet medical needs, particularly in therapeutics and discovery platforms.
Their most common stage is series-b (50% of deals). Average disclosed round size is $62.9M (across 21 rounds with reported amounts).
Portfolio
21
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
24 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 WearLinQ | Series A | $14M | Dec 2025 |
 Maxion | Series A | $72M | Jan 2025 |
| MMaxion Therapeutics Ltd. | Series A | $72M | Jan 2025 |
 Axonis | Series A | $115M | Oct 2024 |
| MMaxion Therapeutics Ltd. | Series A | $16M | Feb 2024 |
| AAxonis Therapeutics | Series A | $115M | Jan 2024 |
 Boxhub | Series A | — | Jun 2023 |
 Ensoma | Series B | $135M | May 2023 |
 Prime Roots | Series B | $30M | May 2023 |
 TiBiT Communications | Series C | $30M | Jun 2022 |
 Carbon Biosciences | Series A | $38M | Jun 2022 |
 Soul Machines | Series B | $70M | Feb 2022 |
| Soul Machines | Series A | $70M | Jan 2022 |
 Immunitas Therapeutics | Series B | $58M | Aug 2021 |
| IImmunitas | Series B | $58M | Aug 2021 |
| CCarisma Therapeutics, Inc. | Series B | — | Mar 2021 |
 ReCode Therapeutics | Series B | $50M | Jan 2021 |
| IImmunitas | Series B | $58M | Jan 2021 |
| RReCode | Series B | $50M | Jan 2021 |
 RideCell, Inc | Series C | $45M | Dec 2020 |
 HotSpot Therapeutics | Series B | $65M | May 2020 |
 CARISMA | Series B | $59M | Jan 2018 |
 Exo Imaging | Growth | — | — |
 Xilio Therapeutics | Series B | $100.5M | — |
Top Co-Investors
AJU IB Investment7 shared
MRL Ventures Fund6 shared
Agent Capital6 shared
Alexandria Venture Investments5 shared
Mirae Asset4 shared
Leaps by Bayer4 shared
Timefolio Capital4 shared
M Ventures4 shared
Cormorant Asset Management3 shared
Sofinnova Partners3 shared
Tekla Capital Management3 shared
Longwood Fund3 shared
BrightEdge3 shared
Ono Venture Investment3 shared
BGF3 shared
General Catalyst3 shared
LifeArc Ventures3 shared
British Patient Capital3 shared
Monograph Capital3 shared
Eli Lilly and Company3 shared
Last updated: 7 October 2026